News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Prostate → cancer profile · × Clear filters
★ 6.0
Nature Cancer
2026-04-15
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177 Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
A substudy of the randomized phase 2 ENZA-p trial, published in Nature Cancer, evaluated the frequency, magnitude, and clinical significance of early prostate-specific membrane antigen (PSMA) upregulation in patients with poor-risk metastatic castration-resistant prostate cancer treated with enzalutamide alone or combined with the radioligand therapy 177Lu-PSMA-617. The findings by Emmett and coll…